
Updated guidance recommends biennial prostate-specific antigen testing for average-risk men aged 50 to 69 years and annual screening beginning at age 45 for higher-risk men.
Hormone Sensitive Metastatic Castration-Resistant Prostate Cancer
Hormone Sensitive mPC progressing to mCRPC
March 2015
H&P:
Imaging:
March 2018



